Drug safety evaluation of olanzapine pamoate

Bibliography

• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161(4):692-9
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
   PubMed Web of Science ®Google Scholar
• Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54(5):665-7
   PubMed Web of Science ®Google Scholar
• Tegeler J, Lehmann E. A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Prog Neuropsychopharmacol 1981;5(1):79-90
   PubMedGoogle Scholar
• Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006;1(1):47-56
   PubMedGoogle Scholar
• Droulout T, Liraud F, Verdoux H. [Relationships between insight and medication adherence in subjects with psychosis]. Encephale 2003;29(5):430-7
   PubMed Web of Science ®Google Scholar
• Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 2006;21(1):29-33
   PubMed Web of Science ®Google Scholar
• Husted JR. Insight in severe mental illness: implications for treatment decisions. J Am Acad Psychiatry Law 1999;27(1):33-49
   PubMed Web of Science ®Google Scholar
• Dam J. Insight in schizophrenia: a review. Nord J Psychiatry 2006;60(2):114-20
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23(4):637-51
   PubMed Web of Science ®Google Scholar
• Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62(7):717-24
   PubMed Web of Science ®Google Scholar
• Abott C, Keith S. Antipsychotic treatment and adherence in schizophrenia. In: Antipsychotic long-acting injections. P, Haddad T, Lambert J, Lauriello, editors. Oxford University Press; Oxford: 2011
   Google Scholar
• Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47(5):741-73
   PubMed Web of Science ®Google Scholar
• Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159(1):103-8
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat 2010;6:573-81
   PubMed Web of Science ®Google Scholar
• Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs 2010;70(17):2289-313
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat 2010;6:261-7
   PubMed Web of Science ®Google Scholar
• Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother 2011;12(4):627-33
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127(1-3):83-92
   PubMed Web of Science ®Google Scholar
• West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008;34(5):995-1001
   PubMed Web of Science ®Google Scholar
• Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67(12):1948-53
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7
   PubMed Web of Science ®Google Scholar
• Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22(5):275-82
   PubMed Web of Science ®Google Scholar
• Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009;23(7):789-96
   PubMed Web of Science ®Google Scholar
• Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2009;175(1-2):58-62
   PubMed Web of Science ®Google Scholar
• Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167(2):181-9
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Andersen SW, Detke HC, et al. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights 2011;3:37-47. Available from: 2728-CMPsy-Long-Term-Safety-and-Tolerability-of-Open-Label-Olanzapine-Long-Acting.pdf
   Google Scholar
• Witte MM, Case MG, Schuh KJ, Ascher-Svanum H. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin 2012;28(3):315-23
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhao F, Detke HC, et al. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry 2011;11:152
   PubMed Web of Science ®Google Scholar
• Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 2011;11:28
   PubMed Web of Science ®Google Scholar
• Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol 2011;26(1):35-42
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/sgow/NCT00320489? term= olanzapine+pamoate&rank=1 [Accessed 30 March.2013]
   Google Scholar
• Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm
   Google Scholar
• Detke HC, Zhao F, Witte MM. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data. BMC Psychiatry 2012;12:51
   PubMedGoogle Scholar
• Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-37
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124(1-2):159-67
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14(2):111-23
   PubMed Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010;10:43
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Kryzhanovskaya LA, Zhao F, et al. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol 2011;26(6):422-33
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Montgomery WS, McDonnell DP, et al. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int J Gen Med 2012;5:391-8
   PubMedGoogle Scholar
• Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
   PubMed Web of Science ®Google Scholar
• Akhras KS, Singh J, Gopal S, et al. Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. Int J Clin Pract 2009;63(6):962-3; author reply 3
   PubMed Web of Science ®Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr Scand 2000;101(6):416-32
   PubMed Web of Science ®Google Scholar
• Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16(2):63-73
   PubMed Web of Science ®Google Scholar
• Patel MX, et al. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010;24(10):1473-82
   PubMed Web of Science ®Google Scholar
• Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68(16):2269-92
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 2009;52:S29-36
   PubMedGoogle Scholar